# Andrew Adams

> Andrew Adams is a Series B investor at Oak HC/FT (New York) backing Health Care and Biotechnology. See 26 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oak HC/FT](https://shizune.co/investors/profile/oak-hc-ft-partners)
- Location: New York, United States
- Total investments: 26
- Last investment: Mar 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/awadams
- Website: https://x.com/andrewadams97

Andrew Adams is a Series B investor at Oak HC/FT in New York focused on Health Care and Biotechnology. Andrew Adams is based out of New York and is the Co-Founder and Managing Partner of Oak HC/FT. Andrew previously worked at Oak Investment Partners as a General Partner. Andrew Adams attended the Princeton University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 50% |
| Biotechnology | 4 | 15% |
| Medical | 3 | 12% |
| Hospital | 3 | 12% |
| Pharmaceutical | 3 | 12% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 23% |
| Series A | 5 | 19% |
| Venture - Series Unknown | 4 | 15% |
| Private Equity | 3 | 12% |
| Series D | 2 | 8% |

10 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Thesis Care | Trovo Health uses AI technology to provide comprehensive healthcare solutions, combining smart algorithms with professional human coaching to deliver personalized patient care. | $45M | Series A | Mar 25, 2026 |  |
| Akido Labs | Akido is a care delivery platform focused on overcoming the complex needs of our most vulnerable populations. We are on a mission to leverage modern technology and proprietary datasets that have historically been locked up in our public health ecosystems in order to radically improve the quality of life and affordability of care for underservedpeople.We are a fast-growing, impact-focused, Y Combinator company being used nationwide to combat the Covid-19 pandemic, homelessness, and other public health crises. Across the country, health systems and government service providers use Akido to launch new technology-powered public health initiatives that improve the health and well-being of the communities they serve. | $60M | Series B | May 15, 2025 |  |
| Remodel Health | Remodel Health provides innovative employee health benefits solutions. The company offers a software platform that helps employers transition to individual coverage health reimbursement arrangements (ICHRA) to provide more personalized and cost-effective health benefits to their employees. Remodel Health is the expert guide for employers andbrokers navigating the complexities of transitioning to ICHRA. They help businesses of all sizes retain more employees by offering individualized health benefits solutions. |  | Private Equity | Dec 19, 2024 |  |
| Remodel Health | Remodel Health provides innovative employee health benefits solutions. The company offers a software platform that helps employers transition to individual coverage health reimbursement arrangements (ICHRA) to provide more personalized and cost-effective health benefits to their employees. Remodel Health is the expert guide for employers andbrokers navigating the complexities of transitioning to ICHRA. They help businesses of all sizes retain more employees by offering individualized health benefits solutions. | $100M | Venture - Series Unknown | Dec 19, 2024 |  |
| Thesis Care | Trovo Health uses AI technology to provide comprehensive healthcare solutions, combining smart algorithms with professional human coaching to deliver personalized patient care. | $15M | Seed | Apr 30, 2024 |  |
| August Bioservices | August Bioservices is a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services. August Bioservices provides comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnologyindustries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch. | $65M | Series B | Dec 01, 2022 |  |
| DispatchHealth | DispatchHealth is a provider of mobile and virtual healthcare for people of all ages in the comfort of their own homes. DispatchHealt was founded in 2013 and was formerly known as True North Health Navigation. It aims to create an integrated, convenient, triage, and care delivery solution that extends the capabilities of the patient's careteam and provides quality care in the home while decreasing costs.It was founded in 2013 and headquartered in Denver, Colorado. | $330M | Series E | Nov 15, 2022 |  |
| Rialtic | Rialtic operates an open marketplace enterprise platform designed to equip and assist payers to make accurate healthcare payments. The company's platform provides a reference source repository, curated material, and payment accuracy technology, allowing users to minimize the total cost of payment accuracy, keep up with changes more easily, andinvent new concepts. | $28M | Series A | Mar 02, 2022 |  |
| Reveleer | Reveleer is a healthcare software and services company that empowers payers in all lines of business to take control of their risk adjustment and quality improvement programs. The platform enables payers to independently execute and manage every aspect of provider outreach, retrieval, coding, abstraction, and reporting – all under one singleplatform. | $65M | Venture - Series Unknown | Dec 07, 2021 |  |
| Infusion for Health | Infusion for Health is a network of ambulatory infusion centers that provides therapies to patients with complex and chronic conditions. | $50M | Venture - Series Unknown | Nov 02, 2021 |  |

10 of 26 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 5 deals together
- [Benchmark](https://shizune.co/investors/profile/benchmark) — VC Fund, 4 deals together
- [DAG Ventures](https://shizune.co/investors/profile/dag-ventures) — VC Fund, 4 deals together
- [Echo Health Ventures](https://shizune.co/investors/profile/echo-health-ventures-llc) — VC Fund, 3 deals together
- [Humana](https://shizune.co/investors/profile/humana) — VC Fund, 3 deals together
- [Maverick Ventures](https://shizune.co/investors/profile/maverick-ventures) — VC Fund, 3 deals together

## About Oak HC/FT

VC Fund · Greenwich, United States

Oak HC/FT is a venture and growth equity investment firm that focuses on healthcare information services and financial service technology. The firm focuses on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, and access to our extensive network of industryleaders.Oak HC/FT partners are peerless in delivering returns for investors and growing innovative businesses. Over the past decade, the partners at Oak HC/FT have had 20 realizations with 6 companies achieving valuations in excess of $1 billion.Oak HC/FT is led by the Healthcare and FinTech team of Oak Investment Partners as part of Oak’s strategy to develop sector-specific funds and continue its legacy of building best-in-class businesses.

5 contacts available at Oak HC/FT.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Adams | Co-Founder & Managing Partner | https://shizune.co/investors/profile/andrew-adams |
| Annie Lamont | Co-Founder & Managing Partner | https://shizune.co/investors/profile/annie-lamont |
| Billy Deitch | Partner | https://shizune.co/investors/profile/billy-deitch |
| Eliza Adams | Investor | https://shizune.co/investors/profile/eliza-adams |
| Michael Heller | Venture Partner | https://shizune.co/investors/profile/michael-heller-3 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Andrew Adams invest in?

Andrew Adams invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Adams last invest?

The most recent investment recorded for Andrew Adams closed in Mar 2026. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co